Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
| Current Price | ₹64.71 |
|---|---|
| Market Cap | ₹140 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | -8.2 |
| Return on Equity | 10.96% |
| 52-Week Range | ₹38.33 – ₹113.50 |
| Beta (1Y) | 1.55 |
| Dividend Yield | 0.00% |
1. Pharma-100%
Krebs Biochemicals & Industries is trading at ₹64.71, with a market capitalisation of ₹140 Cr.
Krebs Biochemicals & Industries operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Krebs Biochemicals & Industries has a P/E of -8.2 and a return on equity of 10.96%.